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Hypoxia-inducible factor (HIF) mediates a broad, con-
served adaptive response to hypoxia, and the HIF path-
way is a potential therapeutic target in cerebral ische-
mia. This study investigated the mechanism by which in
vitro ischemia (oxygen-glucose deprivation; OGD)
affects canonical hypoxic HIF-1a stabilization. We vali-
dated the use of a reporter containing the oxygen-de-
pendent degradation domain of HIF-1a fused to firefly
luciferase (ODD-luc) to monitor quantitatively distinct
biochemical events leading to hypoxic HIF-1a expres-
sion or stabilization in a human neuroblastoma cell line
(SH-SY5Y). When OGD was imposed following a 2-hr
hypoxic stabilization of ODD-luc, the levels of the re-
porter were reduced, consistent with prior models pro-
posing that OGD enhances HIF prolylhydroxylase (PHD)
activity. Surprisingly, PHD inhibitors and proteasome
inhibitors do not stabilize ODD-luc in OGD. Furthermore,
OGD does not affect the half-life of ODD-luc protein fol-
lowing hypoxia, suggesting that OGD abrogates hypoxic
HIF-1a induction by reducing HIF-1a synthesis rather
than by enhancing its degradation. We observed ATP
depletion under OGD vs. hypoxia and propose that ATP
depletion enhances translational suppression, overcom-
ing the selective synthesis of HIF concurrent with global
decreases in protein synthesis in hypoxia. Taken to-
gether, these findings biochemically characterize a prac-
tical reporter for monitoring HIF-1a levels and support a
novel model for HIF regulation in an in vitro model of
human ischemia. VC 2013 Wiley Periodicals, Inc.
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Hypoxia-inducible factor (HIF) is a transcriptional
activator that coordinates evolutionarily conserved adapt-
ive responses to hypoxia (Wang and Semenza, 1993). HIF
is induced in cerebral ischemia (Chavez and LaManna,
2002; Stowe et al., 2008), but perhaps insufficiently; aug-
menting HIF-mediated adaptive responses during cerebral
ischemia may provide novel therapeutic strategies.
HIF is a heterodimer consisting of a constitutively
present b subunit and a short-lived a subunit. HIF-1a
protein half-life is regulated by oxygen-dependent degra-
dation. Under normoxic conditions, prolylhydroxylase
domain enzymes (PHDs) hydroxylate Pro(402) and
Pro(564) on HIF-1a, allowing it to be recognized by the
E3 ubiquitin ligase Von Hippel-Lindau (pVHL) and tar-
geted for proteasomal degradation (Jaakkola et al., 2001;
Ivan et al., 2001; Bruick and McKnight, 2001). Under hy-
poxia, a decrease in PHD activity leads to HIF-1a accu-
mulation, heterodimerization with b subunits, recruitment
of p300/CBP, and transactivation of target gene expres-
sion (Jiang et al., 1996). HIF target genes include VEGF,
EPO, GLUT1, PFK1, neuroglobin, and dozens of other
genes that work in concert to restore oxygen delivery and
to enhance glucose uptake and glycolysis in order to com-
pensate for reduced oxidative phosphorylation.
HIF can be pharmacologically induced by structur-
ally diverse small-molecule PHD inhibitors. PHD inhibi-
tion consistently produces neuroprotection in diverse
neurological disease models, including stroke (Siddiq
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et al., 2005; Nagel et al., 2011), Alzheimer’s disease
(Crapper McLachlan et al et al., 1991; Ritchie et al.,
2003), allergic encephalomyelitis (Bowern et al., 1984),
Parkinson’s disease (Kaur and Andersen, 2004), oxidative
stress (Zaman et al., 1999), excitotoxicity (Li et al.,
2011), trophic factor deprivation (Lomb et al., 2007),
and mitochondrial dysfunction (Niatsetskaya et al.,
2010). PHDs have been identified as the critical targets
of iron chelators such as desferoxamine that are clinically
beneficial in many neurological disorders and that reca-
pitulate the neuroprotective effects of hypoxic precondi-
tioning on later ischemic challenge (Siddiq et al., 2005).
Novel PHD inhibitors poised for clinical trials have been
identified through high-throughput screening (Smirnova
et al., 2010).
Given the evidence for the regulation of HIF-1a
by PHDs, many studies have inferred PHD activity from
HIF levels in the absence of a direct assay of PHD
enzyme activity in vivo. However, HIF stabilization can
occur either via PHD inhibition or by impeding down-
stream parts of the oxygen-dependent degradation do-
main of HIF-1a (ODD) pathway, or through ODD-in-
dependent mechanisms such as p38-MAPK interaction
(Emerling et al., 2005) or NEDD8 conjugation to the
PAS-B domain (Ryu et al., 2011). Likewise, PHD inhi-
bition engages multiple downstream effector pathways in
addition to HIF; some alternative substrates have been
identified that show selectivity among the PHD iso-
forms, including b2-adrenergic receptor (Xie et al.,
2009) and Rbp1 (Mikhaylova et al., 2008). Indeed,
PHD inhibition produces neuroprotection via both
HIF-dependent and HIF-independent mechanisms
(Siddiq et al., 2009). Thus it is critical to decouple meas-
ures of PHD activity from HIF protein level in order to
identify precisely how hypoxic adaptive responses are
regulated under normal and pathological conditions and
how they may be manipulated for therapeutic benefit.
In vitro studies using oxygen and glucose depriva-
tion (OGD) have indicated that disruptions in glucose
supply during cerebral ischemia may curtail endogenous
neuroprotective programs. Glucose is required for
hypoxic HIF stabilization in human mesangial and hepa-
toma (Hep3B) cells (Osada-Oka et al., 2010) and in
human renal carcinoma (UOK262) cells (Sudarshan
et al., 2009). These studies led to a model by which glu-
cose fuels NADPH production through the pentose
phosphate pathway to provide a substrate for NADPH-
dependent oxidases, which in turn produce reactive oxy-
gen species (ROS) that inhibit PHDs. Accordingly, glu-
cose deprivation enhances HIF-1a degradation by reliev-
ing an ROS-mediated inhibition on PHD enzyme activ-
ity. However, it remains unclear 1) whether PHDs in
fact mediate the effects of glucose and 2) whether this
model is applicable to neuronal cells.
Although the potential therapeutic value of HIF in
cerebral ischemia has been widely appreciated for over a
decade, prior studies of HIF regulation in neurons have
been limited by the difficulty of performing quantitative
analysis of immunoblotting employing commercially
available HIF antibodies. Several HIF reporters contain-
ing luciferase and green fluorescent protein (GFP) have
been developed and used for high-throughput screening
for novel HIF activators (Smirnova et al., 2010) and
imaging studies (Safran et al., 2006; Moroz et al., 2009).
However, these studies have looked only at accumula-
tion of the reporter, without investigating the mecha-
nism by which it accumulates. A full-length HIF re-
porter cannot distinguish which domains of the protein
are important, and inclusion of the transactivation do-
main introduces the confound of exaggerating HIF-
mediated gene transcription, thus engaging feedback
loops that may alter HIF regulation. Luciferase has
greater sensitivity and a wider dynamic range than GFP.
Therefore, we used a reporter consisting of the oxygen-
dependent degradation domain of HIF-1a fused to fire-
fly luciferase (ODD-luc), stably expressed in SH-SY5Y
human neuroblastoma cells.
The objectives of this study were 1) to validate the
use of ODD-luc as a quantitative biochemical reporter
for HIF-1a stabilization specifically via the PHD-,
VHL-, and proteasome-dependent pathway and 2) to
apply this tool to test the hypothesis that glucose depri-
vation enhances HIF-1a degradation by increasing PHD
enzyme activity in ischemic human neuronal cells.
MATERIALS AND METHODS
Cell Lines
SH-SY5Y human neuroblastoma cells were maintained
in DMEM/F12 1 Glutamax (No. 10565; Gibco, Grand
Island, NY) with 10% fetal bovine serum, 50 U penicillin/ml,
and 50 lg streptomycin/ml. The ODD-luc construct encoded
in pcDNA3.1 plasmid vector was constructed as described
previously (Safran et al., 2006). A QuikChange Multi Site-
Directed Mutagenesis kit (Agilent Technology, Palo Alto,
CA) was used to introduce the Pro(564)Ala and Pro(567)Ala
mutations for the AYIA control line. Cells were transfected
with 1 microgram plasmid DNA using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Transfected cells were grown in
the presence of 0.5 mg/ml Geneticin (Gibco-Invitrogen).
Cell plating density was optimized for induction of
ODD-luc activity after 2 hr; for all reported experiments, cells
were plated at 5 3 105 cells/ml in volumes of 100 ll/well in
96-well plates or 2.5 ml/well in six-well plates (Corning) 24
hr before treatments. RCC4 cell lines were obtained from
Health Protection Agency Culture Collections (catalog Nos.
03112702 and 03112703) and maintained in DMEM 1 10%
FBS 1 2 mM glutamine 1 G418 0.5 mg/ml (Gibco-Life
Technologies.) Transient transfections of ODD-luc were per-
formed with Lipofectamine 2000 (Invitrogen).
Hypoxic and Drug Treatments
Hypoxia (1% O2, 5% CO2, 94% N2) was induced using
a custom-built hypoxic glovebox (Coy Biosystems). Media
were equilibrated before treatments started, and depletion of
O2 in the media was confirmed with a dissolved oxygen me-
ter (DO 6; Oakton). Cells were washed with warm PBS, then
treated with glucose-free DMEM (No. 11966; Gibco) supple-
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mented with 10% FBS and Pen/Strep and to which glucose
or drugs were added at noted concentrations. Cells were incu-
bated for 2 hr in hypoxia or normoxia (21% O2, 5% CO2) at
378C. Ciclopirox (CPO), 3,4-dihydroxybenzoate (DHB), and
dimethyloxaloylglycine (DMOG) were obtained from Sigma
(St. Louis, MO) and solubilized in water or DMSO at
1,0003 concentrations. Leupeptin and NH4Cl were obtained
from CalBiochem (EMD4 Biosciences, La Jolla, CA).
Luciferase Activity
Luciferase activity and dual luciferase activity assays
(Promega, Madison, WI) were performed according to manu-
facturer’s protocol in 96-well plates. Luminescence was read
with an LMaxII384 luminometer (Molecular Devices, Sunny-
vale, CA) and analyzed in SoftMax Pro software (Molecular
Devices).
Immunoblots
After 2-hr treatments, cells were scraped in ice-cold
PBS and centrifuged at 1,000g for 5 min. The pellet was lysed
in RIPA buffer (1% Triton X-100, 1% SDS, 50 mM Tris-Cl,
pH 7.4, 500 mM NaCl, 1 mM EDTA) plus 1:100 protease
inhibitors cocktail (Sigma), 10 lM MG-132, and 2 ll benzo-
nase (Sigma). Protein concentration was quantified using BCA
(Pierce, Rockford, IL) or QuickStart Bradford (Bio-Rad,
Hercules, CA) assay. Samples were loaded on Nu-PAGE gels
(Life Technologies), transferred to nitrocellulose membranes,
and incubated overnight at 48C with primary antibodies
diluted in Odyssey blocking buffer. Secondary fluorophore-
conjugated Odyssey InfraRedDye-680 and IRD-800 antibod-
ies (LI-COR Biosciences, Lincoln, NE) were added at
1:10,000 in Odyssey blocking buffer and incubated for 1 hr at
RT. Immunoreactive proteins were detected by using an Od-
yssey IR-imaging system (LI-COR Biosciences). Primary anti-
bodies and dilutions used were mouse anti-actin (Sigma)
1:10,000; mouse anti-luciferase sc-74548 (Santa Cruz Biotech-
nology, Santa Cruz, CA) 1:1,000; rabbit anti-HIF-1a NB100-
479 (Novus, Littleton, CO) 1:1,000; and rabbit anti-hydroxy-
HIF-1a Pro(564) D43B5 (Cell Signaling, Beverly, MA).
Viability Assays
Cell viability was assessed by the 4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Life Tech-
nologies) and confirmed by phase microscopy.
ATP Assays
ATP concentration was measured by using an ATP Bio-
luminescent Kit (Sigma). In 96-well plates, cells were lysed
with Cell Culture Lysis Reagent (Promega), a 1:25 dilution of
ATP assay was added and mixed, and luminescence was read
immediately with an LMaxII384 luminometer (Molecular
Devices).
Gene Expression Assays
Cells were lysed in Trizol (Invitrogen) and stored at
2808C. Total RNA was extracted using chloroform phase
separation and isopropanol precipitation according to the
manufacturer’s protocol. Taqman RNA-to-Ct one-step kit
was used with gene expression assays for HIF-1a
(Hs00153153_m1) and b-actin as endogenous control. Quan-
titative real-time PCR was performed using a 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA).
Statistical Analysis
Results are graphed as mean 6 SEM of at least three in-
dependent replicates. ANOVA and Tukey’s post test were
used to determine significance (P < 0.05). Statistical analysis
was performed in GraphPad Prism software.
RESULTS
ODD-Luc Is a Quantitative Reporter for HIF
Stabilization and PHD Activity
HIF-1a protein levels are difficult to study quanti-
tatively in neuronal cells because of the high coefficient
of variation of immunoblots with commercially available
antibodies. A fusion protein containing the oxygen-de-
pendent degradation domain of HIF-1a (a.a. 513–630)
has been previously used as a reporter for HIF-1a stabi-
lization, for high-throughput screening for novel activa-
tors of the hypoxic response (Smirnova et al., 2010), and
for in vivo imaging (Safran et al., 2006; Goldman et al.,
2011). We sought to use the ODD-luc construct as a
biochemical reporter for HIF stabilization through the
canonical PHD-dependent pathway in human neuroblas-
toma (SH-SY5Y) cells. We were interested in the mech-
anism by which HIF is engaged long before sustained
stress leads to cell death, so we measured effects after no
more than 2 hr of hypoxia (1% O2), oxygen and glucose
deprivation (OGD), or drug treatments, a time window
within which no cell death occurs. We first demon-
strated that ODD-luc detection by Western blot with a
monoclonal antibody against firefly luciferase is highly
specific, sensitive, and quantitative over a wide dynamic
range (data not shown).
To ensure that the oxygen-dependent degradation
of ODD-luc is achieved in a manner similar to that of
endogenous full-length HIF-1a, we verified that ODD-
luc activity and protein levels are dose dependently stabi-
lized within 2 hr by structurally diverse PHD inhibitors,
including hypoxia (1% O2); CPO, a specific inhibitor of
the iron-binding site of the HIF prolyl hydroxylases;
3,4-dihydroxybenzoate (DHB), a 2-oxoglutarate analog;
and dimethyloxaloylglycine (DMOG; Fig. 1A.
Canonical hydroxylation of the ODD degron dur-
ing normoxia leads to the recruitment of the E3 ubiqui-
tin ligase Von Hippel Lindau protein (VHL). To deter-
mine whether ODD-luc is degraded in a VHL-depend-
ent manner, we sought to measure ODD-luc
stabilization upon knock-down of VHL in SH-SY5Y
cells; however, we could not confirm pVHL protein
expression in SH-SY5Y cells with commercially avail-
able VHL antibodies. Instead, we transfected ODD-luc
into VHL null human renal carcinoma cells expressing
empty vector (RCC4-EV) or pVHL (RCC4-VHL).
RCC4-VHL cells showed 60% less steady-state ODD-
luc expression than RCC4-EV cells (Fig. 1B), indicating
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that normoxic degradation of ODD-luc is enhanced by
expression of pVHL.
Ubiquitination of HIF-1a is followed rapidly by its
degradation by the 26S proteasome. To verify that
ODD-luc is degraded in a proteasome-dependent man-
ner, we used two structurally diverse proteasome inhibi-
tors, MG-132, a competitive peptide inhibitor, and lac-
tacystin, an irreversible alkylator. Both compounds were
able to dose dependently stabilize ODD-luc as measured
by luciferase activity (data not shown) and Western blot-
ting for luciferase (Fig. 1C).
As expected, proteasome inhibition caused accu-
mulation of a 75-kDa band corresponding to ODD-luc.
Notably, despite the ability of proteasome inhibition to
elevate luciferase activity to a level similar to PHD inhi-
bition, the protein levels of ODD-luc in the proteasome
inhibitor-treated cells were lower. HIF-1a is ubiquiti-
nated at several lysine residues (K532, K538, K547), all
found within the ODD (Paltoglou and Roberts, 2007).
We therefore expected that proteasome inhibitors would
cause accumulation of higher molecular weight bands
corresponding to polyubiquitinated ODD-luc, but we
were unable to detect these bands with the luciferase
antibody or with immunoblot for ubiquitin after immu-
noprecipitation with a luciferase antibody (IP:luc, IB:u-
biquitin) or transfection with HA-ubiquitin followed by
IP:HA, IB:luc, IP:luc, IB:HA, or several other commer-
cially available luciferase antibodies after IP:HA (data not
shown). We conclude that ubiquitination of the ODD-
luc construct partially masks the luciferase epitope but
that ubiquitination does not affect luciferase activity.
We next verified that ODD-luc can be used to
detect PHD-dependent hydroxylation at Pro(564). Using
an antibody that recognizes HIF-1a hydroxylated at
Pro(564), we observed that hydroxylation of ODD-luc
is robust upon stabilization with the proteasome inhibi-
tor MG-132 and is dose dependently diminished by the
PHD inhibitor CPO (Fig. 1D). We further confirmed
specificity of the hydroxyproline immunoblotting by
using a P564A mutant ODD-luc, which showed no
change in luciferase levels with PHD or proteasome in-
hibition and which showed no hydroxylation under any
condition (Fig. 1D). Taken together, these findings con-
firm that the ODD-luc reporter is regulated by PHD,
VHL, and the proteasome in a manner similar to endog-
enous HIF.
OGD Decreases Hypoxic Accumulation of
ODD-Luc
Hypoxia (1% O2, 2 hr) induced ODD-luc activity
approximately sixfold in normal glucose (20 mM), but
decreasing the glucose concentration dose dependently
abrograted the hypoxic induction of ODD-luc, to below
twofold in the absence of glucose, as measured by lucif-
erase activity (Fig. 2A). Hypoxia and OGD had no effect
on cell viability within 2 hr (data not shown). Further-
more, ODD-luc protein levels after 2 hr of hypoxia
Fig. 1. ODD-luc is a biochemical reporter for HIF-1a. A: Luciferase immunoblot after treatment with hypoxia and structurally diverse PHD
inhibitors: 5 or 10 lM ciclopirox (CPO), 0.5 or 1 mM 3,4-dihydroxybenzoate (DHB), and 0.5 or 1 mM dimethyloxaloylglycine (DMOG).
B: ODD-luc activity in RCC4 cells null for, or ectopically expressing, VHL. C: ODD-luc immunoblot after treatment with proteasome
inhibitors: 10 lM MG-132 or 10 lM lactacystin. D: Immunoblot for luciferase or hydroxyproline(564) upon treatment with MG-132 (10
lM) and diminished dose dependently by CPO (micromolar doses as indicated) in wild-type ODD-luc or P564A mutant-expressing cells.
**P < 0.01, ANOVA with post hoc Tukey test.
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were markedly decreased in the absence of glucose (Fig.
2B).
This finding confirmed that OGD abrogates
hypoxic HIF-1a induction by acting on its ODD do-
main in human neuroblastoma cells, consistent with
prior reports using other cell types. Therefore, we sys-
tematically investigated the mechanism by which glucose
affects the ODD, starting with the hypothesis that glu-
cose deprivation enhances PHD enzyme activity.
Glucose Deprivation Does Not Enhance PHD
Activity or Proteasome-Mediated ODD-Luc
Degradation
To determine whether glucose deprivation enhan-
ces PHD enzyme activity in hypoxia, we sought to mea-
sure the effect of OGD on prolyl hydroxylation of
ODD-luc by OH-Pro(564) immunoblot when ODD-
luc degradation was blocked with proteasome inhibition.
Unexpectedly, proteasome inhibition with saturating
doses of MG-132 (up to 20 lM) or lactacystin (up to 10
lM) was not able to accumulate ODD-luc protein in
the absence of glucose, so we could not compare the
hydroxylated fraction of ODD-luc across glucose con-
centrations (Fig. 2B). Indeed, glucose deprivation com-
pletely abolished ODD-luc induction by CPO, MG-
132, or hypoxia as detected by luciferase immunoblot
(Fig. 2B). Therefore, we turned to methods other than
direct measurement of P564 hydroxylation to determine
how OGD negatively regulates HIF.
We reasoned that, if enhanced PHD activity was
responsible for the loss of hypoxic HIF induction in the
absence of glucose, then PHD inhibition should rescue
hypoxic stabilization of ODD-luc under OGD.
Although CPO (10 lM) induced ODD-luc activity
approximately fivefold in normoxia, it had no significant
additive effect on hypoxic ODD-luc induction in nor-
mal glucose and did not significantly increase ODD-
luc levels under OGD (Fig. 2C), suggesting that PHD
enzyme activity was not enhanced by glucose
deprivation.
In light of these results, we hypothesized that glu-
cose deprivation instead enhanced proteasomal degrada-
tion downstream of PHD activity, potentially by
enhancing VHL-mediated ubiquitination or proteasomal
recognition of ODD-luc. We reasoned that if glucose
Fig. 2. Glucose deprivation abrogates hypoxic ODD-luc stabilization in a manner independent of PHD- or proteasome-mediated degradation.
A: ODD-luc activity upon hypoxia (2 hr 1% O2) with varying glucose concentrations. B: ODD-luc protein stabilization by 2 hr treatment
with 10 lM CPO, 10 lM MG-132, or hypoxia in the presence or absence of glucose. C: ODD-luc activity upon treatment with 10 lM
CPO in hypoxia or OGD. D: ODD-luc activity upon treatment with 10 lM MG-132 in hypoxia or OGD. *P < 0.05, **P < 0.01, ***P
< 0.001, ANOVA with post hoc Tukey test.
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deprivation enhanced proteasome-dependent degrada-
tion, then proteasome inhibition should rescue hypoxic
ODD-luc stabilization in OGD. MG-132 (10 lM)
induced ODD-luc activity approximately fivefold in
normoxia, had no significant additive effect on hypoxic
ODD-luc induction in normal glucose, and did not sig-
nificantly increase ODD-luc levels under OGD (Fig.
2D). Taken together, these experiments indicated that
glucose deprivation does not reduce hypoxic HIF induc-
tion through the enhancement of the canonical PHD-
and proteasome-dependent degradative pathway.
Glucose Deprivation Does Not Enhance
ODD-Luc Degradation
HIF-1a can be degraded not only by the 26S pro-
teasome but also by lysosomes; HIF-1a has been
reported to be stabilized by lysosomal inhibition, inde-
pendent of its stabilization by proteasome, HSP90, or
calpain inhibition, downstream of 15-deoxy-
delta(12,14)-prostaglandin-J(2) (Olmos et al., 2009). It is
not known what domain(s) of HIF-1a is necessary for
lysosomal degradation and thus whether the ODD is suf-
ficient for, or more susceptible than endogenous HIF-1a
to, lysosomal degradation. We next investigated whether
glucose deprivation enhances lysosomal degradation of
ODD-luc in ischemic SH-SY5Y cells.
Structurally diverse lysosomal inhibitors NH4CL (5
mM) and leupeptin (250 lM) were unable to stabilize
ODD-luc under 2 hr of OGD (Fig. 3A) and did not
affect cell viability under these conditions. This finding
is consistent with the previous finding that lysosomal
degradation of HIF-1a occurs very slowly (Olmos et al.,
2009) and suggests that enhanced lysosomal degradation
cannot explain the loss of hypoxic ODD-luc induction
in the absence of glucose over the short epoch of obser-
vation used in our analysis.
To examine further whether glucose deprivation
enhances ODD-luc degradation, we measured the half-
life of ODD-luc by blocking protein synthesis with
cyclohexamide (CHX) in the presence or absence of
glucose. In the presence of 10 lg/ml CHX, glucose
concentration had no significant effect on ODD-luc
degradation, with an interpolated half-life of 45.1 min in
normal glucose and 50.6 min in the absence of glucose
(Fig. 3B). Taken together, these data suggest that glucose
deprivation does not enhance HIF-1a degradation
through the ODD domain but may instead suppress
HIF-1a transcription or translation.
Glucose Deprivation Does Not Affect
Transcription of ODD-Luc or HIF-1a
To determine whether glucose deprivation sup-
presses the transcription or translation of ODD-luc in
Fig. 3. Glucose deprivation in hypoxia does not enhance ODD-luc degradation or decrease global transcription, translation, or luciferase ac-
tivity. A: ODD-luc activity after 2 hr hypoxia or OGD in the presence of lysosomal inhibitors NH4Cl 5 mM or leupeptin 250 lM. B:
ODD-luc activity after 2 hr pretreatment with hypoxia followed by 0, 15, 30, 45, or 60 min treatment with cyclohexamide (10 lg/ml) in hy-
poxia with 20 mM glucose (CHX) or 0 mM glucose (CHX 1 GD); C: CMV-luc activity after 2 hr normoxia or hypoxia with glucose con-
centrations from 0 to 20 mM; D: ODD-luc activity after 2 hr hypoxia and cotreatment with actinomycin D at 0.25–8 lg/ml. ***P < 0.001,
ANOVA with post hoc Tukey test.
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hypoxia, we first examined the control construct that
expresses firefly luciferase without the ODD in the same
plasmid vector (CMV-luc). CMV-Luc expression, as
measured by luciferase activity assay or luciferase immu-
noblot, is constitutively much higher than ODD-luc and
is unaffected by hypoxia, PHD inhibition, or proteasome
inhibition (data not shown). CMV-luc expression is
reduced by hypoxia by about 30% (Fig. 3C). This is
consistent with numerous reports of global inhibition of
translation under hypoxia, which occurs rapidly through
PERK and eIF2a phosphorylation and is maintained
over a longer term through mTOR and EIF4e (Liu
et al., 2006; Spriggs et al., 2010). In contrast to ODD-
luc, CMV-luc expression is not affected by glucose con-
centration (Fig. 3C). This suggests that glucose depriva-
tion does not abrogate hypoxic ODD-luc induction via
nonselective suppression of transcription, translation, or
luciferase activity.
We next examined whether transcriptional inhibi-
tion with actinomycin D could mimic the effect of glu-
cose deprivation on ODD-luc levels. Actinomycin D did
not abrogate ODD-luc levels induced by hypoxia within
2 hr (Fig. 3D), indicating that glucose deprivation acts
posttranscriptionally to suppress ODD-luc in hypoxia.
To confirm the relevance of our experiments with
the ODD-luc reporter, we examined endogenous HIF-
1a message and protein levels in wild-type SH-SY5Y
cells treated with CPO, hypoxia, or OGD for 2 hr.
HIF-1a mRNA levels were unchanged by OGD rela-
tive to hypoxia (Fig. 4C), indicating that glucose depri-
vation does not diminish HIF-1a transcription or
mRNA stability. In contrast, HIF-1a protein levels were
decreased in OGD relative to hypoxia (Fig. 4A,B), con-
sistent with the findings using the ODD-luc reporter.
Taken together, these data suggest that glucose depriva-
tion decreases HIF-1a translation under hypoxia.
Glucose Deprivation Decreases ATP Levels
HIF-1a and other stress-responsive genes are pref-
erentially translated even under the global suppression of
protein synthesis that occurs in hypoxia (for review see
Spriggs et al., 2010). We hypothesized that glucose de-
privation produces an additional stress that overwhelms
this selective translation of HIF-1a. Therefore we inves-
tigated how ATP levels are affected in SH-SY5Y cells in
OGD compared with hypoxia alone.
We measured ATP concentration in cells treated
with CPO, hypoxia, or OGD for 2 hr. ATP levels were
not significantly affected by CPO or hypoxia, but
were reduced by approximately 50% after 2 hr OGD
compared with hypoxia (Fig. 4D). As in previous
Fig. 4. OGD compared with hypoxia alone abrogates endogenous HIF-1a protein but not mRNA levels and reduces cellular ATP levels after
2-hr treatments with 10 lM CPO, hypoxia (1% O2, 20 mM glucose), or OGD (1%O2, 0 mM glucose). A: Representative immunoblot for
HIF-1a. B: HIF-1a protein stabilization measured by densitometric analysis of three immunoblots. C: HIF-1a mRNA determined by qRT-
PCR with b-actin as endogenous control. D: ATP concentration, relative to untreated control. *P < 0.05, **P < 0.01, ***P < 0.001, n.s.
no significant difference. ANOVA with post hoc Tukey test.
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experiments, there was no difference in cell viability
with any treatment within 2 hr (not shown).
DISCUSSION
We have demonstrated for the first time that com-
bined OGD suppresses hypoxic HIF induction in human
neuronal cells, consistent with findings in other cell
types, including rat cortical neurons (Guo et al., 2008),
human hepatoma (Hep3B) cells (Osada-Oka et al.,
2010), and human renal carcinoma (UOK262) cells
(Sudarshan et al., 2009). Using our ODD-luc reporter,
we systematically investigated the mechanism by which
glucose modulates HIF-1a protein levels and found that
glucose deprivation does not enhance PHD-dependent
HIF-1a degradation; rather, we observe that glucose de-
privation leads to ATP depletion and overcomes the
selective synthesis of HIF-1a within the context of
global translational suppression in hypoxia.
Several mechanisms have been proposed to explain
the continued synthesis of HIF-1a during global transla-
tional suppression in hypoxia. HIF-1a mRNA is selec-
tively stabilized in hypoxia by RNA binding proteins
that recognize the 50 and 30 untranslated regions (UTRs;
Galba´n et al., 2008). The HIF-1a 50 UTR has been
reported to contain an internal ribosome entry site
(IRES), although this is controversial (for review see
Spriggs et al., 2010). Other stress-responsive proteins
including ATF4 contain ‘‘decoy’’ upstream open reading
frames, which may also be present in HIF-1a (Spriggs
et al., 2010). None of these mechanisms can explain our
finding with the ODD-specific reporter. The fact that
the ectopically expressed ODD-luc protein (but not the
CMV-luc control protein) is regulated by glucose at the
level of synthesis suggests that HIF-1a translation is
regulated at least in part by the ODD portion of the
coding region, a novel insight that should be verified
with endogenous HIF-1a.
One way in which glucose deprivation could sup-
press HIF-1a synthesis in hypoxia is via activation of
AMP-activated protein kinase (AMPK). AMPK is a key
integrator of metabolic homeostasis. As part of its pro-
gram to reduce ATP demand in times of scarcity,
AMPK suppresses protein synthesis through two distinct
mechanisms. First, AMPK activates TSC2, which inhib-
its mTOR, thus reducing activity of ribosomal S6 kinase
and eukaryotic initiation factor-4 (eIF4). Second, AMPK
activates eukaryotic elongation factor-2 (eEF2) kinase,
leading to the phosphorylation and inhibition of eEF2.
AMPK becomes activated by phosphorylation at threo-
nine 172, which occurs in an LKB1-dependent manner
upon ATP depletion or several other forms of cellular
stress, including sustained hypoxia. Serum deprivation
has been reported to accelerate hypoxic AMPK activa-
tion and subsequent inhibition of protein synthesis in
hypoxia from 20 hr to 30 min (Liu et al., 2006). We
propose that glucose deprivation has synergistic effects
similar to serum deprivation in the context of hypoxia.
AMPK phosphorylation occurs in ischemia in vivo
and contributes to injury; inhibiting pAMPK reduces
infarct volume and behavioral deficits, and pAMPK
downregulation is essential for neuroprotection by ische-
mic preconditioning (Li et al., 2010; Venna et al., 2012).
This is consistent with the notion that neuronal resilience
to ischemia can be enhanced by sustaining the synthesis of
HIF-1a, so that stress-sensitive posttranslational check-
points allow it to engage a broad adaptive response when
appropriate. On the other hand, increasing HIF-1a pro-
tein levels outright has produced conflicting effects. In
vivo models show that HIF can prevent injury (Baranova
et al., 2007) and improve functional recovery (Wu et al.,
2010), increase infarct and edema volume (Chen et al.,
2008; Higashida et al., 2011), or have opposing effects at
progressive times after stroke (Yeh et al., 2010). In vitro
models also show that HIF either protects or exacerbates
cell death via expression of target genes that encode both
prosurvival and proapoptotic proteins (Aminova et al.,
2005; Guo et al., 2009) and demonstrate divergent roles
of HIF in distinct CNS cell types (Vangeison et al., 2008).
In contrast to direct HIF manipulation, PHD inhibition is
broadly neuroprotective, as discussed above. Together
these observations highlight the need to decouple meas-
urements of PHD enzyme activity from HIF protein lev-
els in order to identify the optimal therapeutic targets
within hypoxia-responsive pathways. We validated the
utility of the ODD-luc reporter as a quantitative assay for
ODD-specific regulation of HIF protein levels. Although
pathophysiological regulation of the reporter’s synthesis
constrains its usefulness in ischemia, we validated that im-
munoblotting for hydroxy-P564 on ODD-luc can serve
as a highly quantitative direct assay of PHD enzyme activ-
ity, a valuable resource for future studies of the mecha-
nisms of HIF regulation.
NADPH supplementation has been reported to res-
cue hypoxic HIF accumulation under glucose depriva-
tion, suggesting that glucose is required to replenish
NADPH through the pentose phosphate pathway
(Osada-Oka et al., 2010). In light of our findings, it is
possible that NADPH bolsters HIF-1a accumulation in
OGD not via ROS regulation of PHDs but instead by
supporting energy homeostasis and preventing AMPK-
mediated suppression of HIF-1a translation. In addition,
Guo and colleagues have found that in cortical neurons
glucose maintains a reducing environment (e.g., through
NADPH facilitating GSH regeneration from GSSG via
glutathione reductase), supporting a model by which
ROS induces HIF-1a degradation under hypoxia, in
contrast to findings in other systems that ROS can stabi-
lize HIF-1a (Ryu et al., 2011) or that mitochondrial
ROS production is in fact necessary for the hypoxic sta-
bilization of HIF-1a (Guzy and Schumacker, 2006). We
saw no effect of structurally diverse antioxidants on
hypoxic ODD-luc accumulation in normoxia or hypoxia
in SH-SY5Y cells (data not shown), suggesting that any
effect of ROS on HIF-1a protein levels in these cells
occurs through ODD-independent mechanisms, e.g.,
not through ROS-mediated inhibition of PHDs.
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Our finding of abrogated HIF-1a induction in
OGD in vitro is not inconsistent with reports of HIF-1a
protein accumulation in ischemia in vivo, because ische-
mic pathology unfolding in an intact brain involves
diverse factors such as inflammation that may induce
HIF-1a levels independent of mechanisms elucidated
here.
Redundancy in the mechanisms by which HIF-1a
may be induced highlights its importance and its poten-
tial power as a therapeutic target. The present study sug-
gests that augmenting HIF signaling in ischemic neurons
will be achieved not through antioxidant or PHD inhi-
bition strategies but rather by targeting ATP homeostasis
and/or translational regulation, a premier candidate for
which is AMPK. It remains to be determined whether
HIF protein levels correlate with cellular health in the is-
chemic human brain. Additionally, our data suggest that
any neuroprotective effects of PHD inhibition in neuro-
nal ischemia may be working through HIF-independent
mechanisms given the scarcity of HIF when glucose is
limiting.
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